Key Takeaways
- Wall Street analysts project an average price target of $89.36 for RKLB, representing approximately 33% potential upside
- The company secured a $190M Department of Defense contract for hypersonic testing missions, driving backlog above $2 billion
- Clear Street launched coverage with a Buy recommendation and $88 target price
- Neutron rocket hardware has reached final assembly stage, targeting Q4 2026 maiden flight
- Company insiders have divested more than $136M in shares over the previous three months, sparking dilution questions
Rocket Lab (RKLB) has experienced a roughly 6.5% decline recently, currently trading around $67.23. However, Wall Street analysts remain optimistic about the stock’s trajectory.
The consensus analyst price target stands at $89.36 — representing approximately 33% upside from present levels. Among coverage analysts, nine have issued Buy ratings while four maintain Hold recommendations.
The recent price weakness arrives despite multiple favorable company developments. Broader aerospace and defense sector headwinds, driven by Middle Eastern geopolitical instability, have temporarily pressured RKLB shares.
The most significant recent announcement involves a $190 million Department of Defense agreement. This contract encompasses up to 20 HASTE hypersonic test missions — marking the largest launch services agreement in the company’s history. CEO Sir Peter Beck described it as a “proud moment.”
Today Electron took to the skies for our 84th launch, delivering mission success for @synspective. And we're not done yet. We have another 19 launches on the books for @synspective alone as we build out their constellation by 2028. pic.twitter.com/E61zUiuFxa
— Rocket Lab (@RocketLab) March 20, 2026
This defense contract elevated Rocket Lab’s total contracted backlog beyond the $2 billion threshold. This represents a substantial revenue pipeline for upcoming quarters.
The company also successfully executed its 84th Electron mission — marking the 8th launch for customer Synspective. This successful deployment demonstrates consistent launch execution and durable customer partnerships with constellation operators.
Neutron Development Advances Toward Inaugural Flight
The Neutron launch vehicle represents the company’s primary long-term growth catalyst. This 43-meter partially reusable rocket targets satellite constellation deployment and cargo transportation missions. The vehicle positions Rocket Lab as a direct competitor to SpaceX’s Falcon 9 platform.
Critical hardware components — including the distinctive “Hungry Hippo” payload fairing and primary thrust structure — have completed production and entered final integration. The inaugural launch remains scheduled for the fourth quarter of 2026, following a minor manufacturing-related timeline adjustment.
Clear Street analyst Gregory Pendy recently launched coverage with a Buy rating and $88 price objective. He highlighted the company’s vertically integrated manufacturing approach as a strategic advantage, projecting Electron launch cadence to reach approximately 52 annual missions by 2030.
Cantor Fitzgerald analyst Andres Sheppard maintained his Buy recommendation with an $85 target, identifying Neutron’s first orbital flight as the most critical near-term catalyst for share price appreciation.
Significant Insider Selling Activity
Not all indicators point upward. Company insiders have executed substantial share sales recently. CFO Adam Spice divested 62,744 shares at $69.59 in early March, reducing his holdings by 4.61%. Insider Frank Klein sold 36,768 shares at $71.95 shortly thereafter.
Collectively, company insiders have liquidated over 1.81 million shares valued at approximately $136.5 million during the past 90 days. This activity has drawn attention from investors monitoring potential dilution concerns, particularly following a recent equity capital raise.
Institutional investor activity presents a contrasting narrative. Swiss Life Asset Management expanded its position by 480.9%, acquiring 48,369 shares. AQR Capital Management increased its stake by 114%. Institutional ownership currently represents 71.78% of outstanding shares.
Morgan Stanley elevated RKLB from Equal Weight to Overweight in January, raising its price objective to $105. Needham maintains a Buy rating with a $95 target. Zacks transitioned to Hold in February.
RKLB’s 52-week trading range extends from $14.71 to $99.58. The stock’s 50-day moving average currently sits at $76.31.
